skip to the content

ACTEMRA

in combination with MTX

is effective in reducing

signs and symptoms in

DMARD-IR patients.

TOWARD

Tocilizumab in cOmbination With traditional DMARD therapy

The TOWARD trial evaluated 1,220 patients who had an inadequate response to their existing rheumatologic therapy, including one or more disease modifying anti-rheumatic drugs (DMARDs). Doses of 8 mg/kg ACTEMRA or placebo were given every four weeks in combination with stable DMARDs.

Summary of results

Compared with controls treated with placebo plus DMARDs, patients in the ACTEMRA 8 mg/kg plus DMARDS arm had superior American Collage of Rheumatology (ACR) 20 (60.8% vs. 24.5%), ACR50 (37.6% vs. 9.0%) and ACR70 (20.5% vs. 2.9%) responses (p<0.0001 for each) and more patients achieved Disease Activity Score (DAS) 28 remission at 24 weeks (30.2% vs. 3.4%, p<0.0001). CRP levels were normalised in patients in the ACTEMRA 8 mg/kg plus DMARDs arm within 2 weeks of the first infusion and remained low throughout the study. Patients in the
ACTEMRA 8 mg/kg arm also showed significant improvements in physical function (health assessment questionaire-disability index [HAQ-DI] score) and fatigue (functional assessment of chronic illness therapy-fatigue [FACIT-Fatigue] score).

ACTEMRA combined with DMARDs was an effective and well-tolerated therapeutic approach in patients with moderate to severe active rheumatoid arthritis (RA) with an inadequate response to a DMARD.

Genovese MC, et al. Arthritis Rheum 2008;58:2968-2980.